Buprenorphine

Major

Buprenorphine Oxycodone Oxaydo Explained Reduced analgesic effect or precipitation of withdrawal symptoms, and an increased risk of serotonin syndrome Details Buprenorphine Oxymorphone Explained Reduced analgesic effect or precipitation of withdrawal symptoms and an increased risk of serotonin syndrome Details Buprenorphine Ozanimod Explained An increased risk of serotonin syndrome or opioid-related toxicity, an increased risk of serious adverse reactions and additive ef... Details Buprenorphine Pacritinib Vonjo® Explained An increased risk of QT interval prolongation Details Buprenorphine Palbociclib Ibrance Explained Increased buprenorphine exposure and an increased risk of buprenorphine-related adverse events Details Buprenorphine Paliperidone Erzofri Explained An increased risk of CNS depression, an increased risk of QT interval prolongation and torsade de pointes Details Buprenorphine Palonosetron Explained An increased risk of serotonin syndrome Details Buprenorphine Panobinostat Farydak Explained An increased risk of QT interval prolongation Details Buprenorphine Papaveretum Explained An increased risk of serotonin syndrome and an increased risk of respiratory and CNS depression Details Buprenorphine Papaverine Pavacot® Explained An increased risk of QT interval prolongation Details Buprenorphine Paregoric Explained An increased risk of serotonin syndrome and an increased risk of respiratory and CNS depression Details Buprenorphine Paroxetine Paxil Explained An increased risk of QT interval prolongation, an increased risk of serotonin syndrome and an increased risk of paralytic ileus Details Buprenorphine Pasireotide Signifor Explained An increased risk of QT interval prolongation Details Buprenorphine Pazopanib Votrient Explained An increased risk of QT interval prolongation Details Buprenorphine Pentamidine NebuPent Explained An increased risk of QT interval prolongation Details Buprenorphine Pentazocine Explained Reduced analgesic effect or precipitation of withdrawal symptoms, and an increased risk of serotonin syndrome and respiratory depr... Details Buprenorphine Pentobarbital Fatal-Plus Explained An increased risk of respiratory depression and CNS depression Details Buprenorphine Perampanel FYCOMPA Explained An increased risk of respiratory depression and CNS depression Details Buprenorphine Perazine Explained An increased risk of respiratory depression and CNS depression Details Buprenorphine Periciazine Explained An increased risk of respiratory depression and CNS depression Details Buprenorphine Perphenazine Explained An increased risk of QT interval prolongation, an increased risk of CNS and respiratory depression and an increased risk of paraly... Details Buprenorphine Phenobarbital Fidoquel Explained An increased risk of QT interval prolongation, an increased risk of CNS depression, reduced buprenorphine exposure and reduced eff... Details Buprenorphine Phenytoin Dilantin Explained Reduced buprenorphine exposure and reduced efficacy of buprenorphine Details Buprenorphine Pimavanserin Nuplazid Explained An increased risk of QT interval prolongation Details Buprenorphine Pinazepam Explained An increased risk of CNS depression and respiratory depression Details Buprenorphine Pipamperone Explained An increased risk of QT interval prolongation Details Buprenorphine Pipenzolate Bromide Explained An increased risk of paralytic ileus Details Buprenorphine Piperacetazine Explained An increased risk of respiratory depression and CNS depression Details Buprenorphine Pipotiazine Explained An increased risk of respiratory depression and CNS depression Details Buprenorphine Pirenzepine Explained An increased risk of paralytic ileus Details Buprenorphine Piretanide Explained Reduced efficacy of diuretics Details Buprenorphine Piritramide Explained An increased risk of serotonin syndrome and an increased risk of respiratory and CNS depression Details Buprenorphine Pitolisant Wakix Explained An increased risk of QT interval prolongation Details Buprenorphine Polythiazide Explained Reduced efficacy of diuretics Details Buprenorphine Ponesimod Ponvory Explained An increased risk of QT interval prolongation Details Buprenorphine Potassium Oxybate Xywav Explained An increased risk of CNS depression and clinically significant respiratory depression, obtundation, hypotension, profound sedation... Details Buprenorphine Prazepam Explained An increased risk of CNS depression and respiratory depression Details Buprenorphine Prednisone Deltasone Explained Reduced buprenorphine exposure and reduced efficacy of buprenorphine Details Buprenorphine Pregabalin Bonqat Explained An increased risk of respiratory depression Details Buprenorphine Primidone Mysoline Explained An increased risk of QT interval prolongation, an increased risk of CNS depression, reduced buprenorphine exposure and reduced eff... Details